Fulcrum Therapeutics, Inc. (FULC)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | — | ||
| 10-Q | Q1-2026 | 8-K (2026-04-27) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-24) · 99.1 | 8-K (2026-01-12) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-10-29) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-07-29) · 99.1 · 99.2 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-01) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-25) · 99.1 | 8-K (2025-01-13) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-13) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-07-31) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-13) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-27) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-07) · 99.1 | ||
| 10-K/A | FY-2022 | |||
| 10-K/A | FY-2021 | |||
| 10-K/A | FY-2020 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive (loss) Income (unaudited) | — |
|
| Consolidated Statements of Operations and Comprehensive Income (loss) (unaudited) | — |
|
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (deficit) | — |
|
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Additional Balance Sheet Detail | ||
| Cash Equivalents and Marketable Securities | ||
| Collaboration and License Agreements | ||
| Commitments and Contingencies | ||
| Common Stock | ||
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Defined Contribution Plan | ||
| Fair Value Measurements | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Leases | ||
| License Agreements | ||
| License and Collaboration Agreements | ||
| Nature of The Business and Basis of Presentation | ||
| Net (loss) Income Per Share | — |
|
| Net Income (loss) Per Share | — |
|
| Net Loss Per Share | ||
| Pay Vs Performance Disclosure | ||
| Preferred Stock | ||
| Property and Equipment, Net | ||
| Related-party Transactions | ||
| Restructuring Activities | ||
| Restructuring Expenses | — |
|
| Right of Reference and License Agreement | — |
|
| Segment Information | ||
| Stock-based Compensation Expense | ||
| Subsequent Events | — |
|
| Summary of Significant Accounting Policies | ||